Parkinson’s treatment side effects: dizziness, hallucinations, dyskinesia and new symptoms

Walking may become easier while standing causes dizziness. A new medicine may relieve stiffness but be followed by seeing people who are not there. These trade-offs deserve prompt feedback rather than leaving patients to choose alone between tolerating every problem and stopping all treatment. Symptoms may reflect Parkinson’s disease, medication, another illness or several factors together. The clinician needs the onset, severity and actual regimen to interpret them. Chinese Parkinson’s disease treatment guideline, fifth edition

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

A side-effect record can be simple. Note when the symptom began, which medicine or formulation had recently changed, how long it lasts and whether it affects eating, walking or safety. Bring prescriptions, packaging and actual dose times, including blood-pressure treatments, psychiatric medicines, analgesics, antiemetics and supplements from other sources.
A pharmacovigilance case analysis published in 2026 examined amantadine-associated corneal edema, highlighting the need to assess blurred or declining vision. Case reports cannot supply an accurate incidence for all users, but can identify an important safety signal. A visual change should not automatically be attributed to aging or dry eyes. Safety study of amantadine and corneal edema
The hospital should provide clear review and urgent-contact arrangements, explaining which problems can be reported remotely and which require local examination. Before returning home, retain generic names, strengths, release forms, change dates and device details rather than only Chinese brand names. Obtain local emergency care for severe new symptoms before coordinating records with the original team.

Quick answer

Full guide

Keep a usable record of what changed

A side-effect record can be simple. Note when the symptom began, which medicine or formulation had recently changed, how long it lasts and whether it affects eating, walking or safety. Bring prescriptions, packaging and actual dose times, including blood-pressure treatments, psychiatric medicines, analgesics, antiemetics and supplements from other sources.

Breathing difficulty, severe allergic symptoms, a seizure, a major change in awareness or new one-sided weakness warrants urgent medical assessment. Tell the receiving team about Parkinson’s disease and current treatment without deciding in advance that every emergency is drug-related. Clinicians can then determine what should continue, change or be withheld.

The record should help assessment rather than delay it. When the problem is severe, seek care first and let a companion gather the remaining information. Keep an easily accessible current medication list so that it does not need to be reconstructed under pressure.

Dizziness on standing requires a whole-regimen review

Orthostatic hypotension may involve autonomic dysfunction, dehydration or medication. NICE recommends reviewing possible contributors across the prescription, including antihypertensive, dopaminergic, anticholinergic and antidepressant medicines. Focusing only on the newest tablet may miss the explanation, while independently stopping all blood-pressure treatment creates another risk. NICE recommendations on orthostatic hypotension

Describe the transition from lying to sitting and standing, any dimming of vision or near-fainting, and whether the problem occurs after meals. Obtain guidance on home measurement methods and timing; do not remain standing unsafely just to capture a reading. Extra salt or fluid and medicines that raise pressure are not appropriate for everyone, particularly with heart failure, kidney disease or high supine pressure.

Report falls and near misses as well as measured blood pressure. The practical aim is safer function, not merely a reassuring number recorded while seated in the clinic. Ask who will coordinate changes when several prescribers are involved.

Sleepiness and sudden sleep episodes affect driving

Dopaminergic treatment can be associated with sleepiness or sleep attacks, sometimes without a warning the patient recognizes. Work demands, driving, night-time sleep and other sedating medicines should be discussed when selecting and reviewing dopamine agonists. Falling asleep during driving or conversation is significant even if the person describes feeling only mildly tired. AAN guideline on dopaminergic treatment

Stop driving and other hazardous activities if these events occur, and contact the clinician promptly. Coffee or opening a car window does not substitute for assessment. A family member can record what the patient was doing, whether warning symptoms occurred and how long the event lasted.

Explain whether the symptom began after a change or appeared on an apparently stable regimen. The review may involve medication adjustment or further sleep assessment. Do not assume that having tolerated a medicine previously removes the need to report a new problem.

Impulse-control changes may be difficult to disclose

Changes in gambling, spending, sexual urges, eating or repetitive activity can be treatment-related. Longitudinal research links dopamine agonist exposure with impulse-control difficulties. A new loss of control should not simply be interpreted as a character change, and embarrassment should not delay help until financial or relationship harm becomes severe. Longitudinal study of dopamine agonist-related behavioral risk

Agree a way to contact the team if unusual spending or uncontrollable urges persist. Discuss temporary protective measures with the patient’s participation where possible. Treatment may involve gradual medication adjustment and psychological support. The patient should have an opportunity to speak privately.

Abruptly withholding medication as a punishment or an attempt to control behavior is inappropriate and may produce further symptoms. Ask the clinical team how the family can support the plan and what changes need urgent attention. Caregivers may also need support after a period of conflict or financial stress.

Hallucinations and acute confusion need different levels of assessment

Clinicians distinguish longstanding hallucinations from newly altered attention or awareness and investigate possible infectious, metabolic or medication triggers. Psychiatric treatment in Parkinson’s disease must consider motor function; familiar sedatives or antipsychotics are not automatically suitable. If the person cannot remain safe, or acute confusion accompanies substantial physical illness, seek timely medical care. German Society of Neurology guideline on psychiatric symptoms and delirium

Explain whether the patient recognizes that an image may not be real and whether fear leads to leaving home or refusing medicines. Mention recent poor sleep, illness and prescription changes. Families can offer calm orientation and company rather than escalating an argument about what the patient perceives.

An adjustment plan should be understandable to the patient and caregiver, with a stated review interval and reasons to seek help sooner. When a medicine is reduced, observe both the psychiatric symptom and movement control so the prescriber can evaluate the complete effect.

Increased movement may be dyskinesia

Dyskinesia can appear when dopaminergic effects become stronger and does not always resemble typical tremor. Opicapone’s label, for example, warns that enhancement of levodopa’s effects may cause or worsen dyskinesia and require adjustment elsewhere in the regimen. This should not automatically be interpreted as worsening Parkinson’s disease requiring further escalation. Official opicapone prescribing information

Describe whether movement interferes with sitting, meals, speech or sleep and how long after a dose it occurs. Mild movement that does not trouble the patient creates a different trade-off from dyskinesia affecting safety. A video may help identification, but do not ask the person to attempt an unsafe activity or take extra medication to reproduce it.

Ask the clinician how the distinction will affect treatment. The patient’s description is useful even if the correct medical term is unknown. What matters initially is an accurate account of the appearance, timing and functional consequence.

New visual changes during amantadine treatment deserve attention

A pharmacovigilance case analysis published in 2026 examined amantadine-associated corneal edema, highlighting the need to assess blurred or declining vision. Case reports cannot supply an accurate incidence for all users, but can identify an important safety signal. A visual change should not automatically be attributed to aging or dry eyes. Safety study of amantadine and corneal edema

The specific amantadine preparation also requires a check of renal restrictions, and different release formulations are not automatically substitutable. The 2026 GOCOVRI information includes hallucination and blood-pressure warnings and advises against abrupt discontinuation. Have the clinician arrange evaluation and adjustment rather than replacing the capsule with another formulation independently. Current GOCOVRI prescribing information

Bring the product details to the eye assessment and make sure the neurological prescriber receives the findings. When two specialties are involved, clarify which clinician will coordinate a treatment change. The aim is to address the visual concern while maintaining a safe Parkinson’s regimen.

Vitamin B6 monitoring changed in 2026

On March 20, 2026, the FDA required relevant carbidopa/levodopa-containing products to carry warnings about vitamin B6 deficiency and associated seizures. The communication recommends assessment before treatment, periodically during use and when suggestive symptoms occur, with supplementation as needed. Ask whether your particular medicine falls within the described group and who will arrange monitoring. FDA vitamin B6 safety communication

Numbness, tingling or confusion has several possible causes; do not diagnose deficiency independently and begin high-dose supplementation. Seizures require urgent care, with the complete medicine and vitamin history available. A US safety communication does not establish that every Chinese combination product has already undergone the same label revision. Monitoring and prescribing need the current product information and individual clinical context.

List all existing supplements at review. The team needs to know the ingredients and actual use when interpreting results or advising additional treatment. A clear plan for testing and follow-up is more useful than leaving a newly identified warning as an unresolved worry.

Infusion-site problems need a contact and continuity plan

Continuous subcutaneous treatment can cause local pain, redness or nodules and may involve infection. The VYALEV label requires training, aseptic technique, site rotation as directed and a backup approach for interruptions. Skin care and delivery cannot be considered entirely separately because a site change or pause can alter medication delivery. VYALEV prescribing information, 2026

Expanding redness, purulent discharge or fever warrants prompt contact with a medical service. Do not keep inserting a cannula into abnormal skin, or allow a prolonged interruption without understanding the prescribed backup plan. Before traveling, confirm consumables and the route for advice.

Photographs can support communication, but a clinician must decide whether examination is needed. Record when the change was noticed and whether infusion was interrupted. This helps the team address both the local problem and the patient’s movement symptoms.

Antiemetics and cough remedies can also interact

Patients using apomorphine infusion should not independently add ondansetron or another 5-HT3 antagonist for nausea. ONAPGO’s label contraindicates these combinations because profound hypotension and loss of consciousness have been reported. A clinician familiar with the Parkinson’s regimen should select a response to nausea. ONAPGO prescribing information, 2026

Safinamide also has interactions involving dextromethorphan and selected analgesic or psychiatric medicines. When buying an over-the-counter product, show the pharmacist the active medication list rather than asking only whether it is suitable for an older person. The appropriate response to the same symptom may differ between regimens. Official safinamide prescribing information

Retain the ingredient list of combination cold remedies. A familiar brand name can represent more than one formulation, and multiple products may contain overlapping ingredients. Clear information helps the pharmacist or prescriber provide a specific answer.

Give new postoperative difficulties their procedural context

If speech, balance or mood changes after DBS implantation or programming, explain whether it followed surgery, a setting change or a medication reduction. Assessment needs to distinguish procedural, stimulation, medication and disease effects; it cannot promise that every problem can be reversed by programming. The 2026 DBS consensus includes these functions in counseling and assessment, making a comparable pre-treatment record useful. Consensus on functional assessment around DBS

After a lesion procedure, also supply the target, side and date, because these affect interpretation. Persistent new symptoms should not receive only a general reassurance that recovery is ongoing. Ask what supports continued observation, when reassessment is planned and which change would require earlier action.

Arrange follow-up after treatment in China

The hospital should provide clear review and urgent-contact arrangements, explaining which problems can be reported remotely and which require local examination. Before returning home, retain generic names, strengths, release forms, change dates and device details rather than only Chinese brand names. Obtain local emergency care for severe new symptoms before coordinating records with the original team.

After a side-effect intervention, reassess control of the original problem as well. Have OFF periods increased after reducing hallucinations? Has changing a blood-pressure-related medicine affected another condition? Charges for additional tests, treatment and visits need individual confirmation; this article does not promise a standard fee or reimbursement.

The practical objective is a treatment balance that can be maintained and reviewed. No single appointment can guarantee removal of every risk, but it can establish what to observe, who will respond and how the next decision will be made.